Trial Profile

A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC 673089) Versus Weekly Paclitaxel With Oncolytic Reovirus (Reolysin NSC 729968) in the Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pelareorep (Primary) ; Paclitaxel
Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Adverse reactions; Therapeutic Use

29 Aug 2020 Status changed from active, no longer recruiting to completed.
12 Sep 2017 Results (n=563) of pooled data from eight trial (NCI-GOG 0186H, NCI-8601, NCIC-CTG IND.213, REO011, REO015, REO016, REO018 and REO021) assessing the safety and tolerability of intravenous pelareorep in combination with chemotherapy, were presented at the 42nd European Society for Medical Oncology Congress.
27 Jul 2017 Results (n=108;from December 2010 to September 2014) published in the Gynecologic Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com